Processes for making aryl compounds that modulate ikzf2
EP4750463A2Pending Publication Date: 2026-06-03PLEXIUM INC
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- PLEXIUM INC
- Filing Date
- 2024-07-26
- Publication Date
- 2026-06-03
AI Technical Summary
Technical Problem
Current therapies targeting regulatory T cells in tumors using anti-CTLA4 antibodies often cause systemic activation of T-effector cells, leading to excessive toxicity and limited therapeutic utility.
Method used
Development of IKZF2-specific modulators or degraders that can selectively target regulatory T cells in tumors without activating T-effector cells, thereby reducing systemic toxicity.
Benefits of technology
The proposed process for synthesizing IKZF2-specific modulators or degraders allows for more efficient preparation of optically pure compounds with fewer synthetic steps, reduced waste, and less chromatographic purification, potentially leading to a more tolerable and less toxic therapy for cancer treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000002_0001 
Figure IMGF000003_0001 
Figure IMGF000003_0002
Abstract
The present disclosure relates generally to processes for preparing compounds that bind to cereblon, thereby modulating cereblon activity, and the synthetic intermediates prepared thereby.
Need to check novelty before this filing date? Find Prior Art